Inert Dusts and Pathology of Chronic Obstructive Pulmonary Disease
NCT ID: NCT00618137
Last Updated: 2012-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
160 participants
OBSERVATIONAL
2007-01-31
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Secondary endpoints Assessment of occupational and environmental exposure to primarily inert fine dusts in a random subset of the strata by means of 24h-measurement of quantity and quality of fine dust inhalation; Influence of intensified exposure to fine dusts due to occupational conditions; Development of lung function in the five different study groups (see below), particularly changes from one GOLD class into the next class;
Definition of Study Groups:
Group 1 (Control):
Healthy volunteers, age 18 to 35 yr, never smokers (n=20).
Group 2 (preferentially taxi or bus drivers; COPD °0):
Working men/women, age 18 to 65 yr, preferentially taxi drivers or bus drivers or comparable occupational burden, current smokers or ex-smokers, with symptoms suggestive of COPD, yet regular lung function test at rest at the time of study entry, no signs of significant other diseases, in particular no signs of cardiovascular disease (n=35).
Group 3 (preferentially taxi or bus drivers; COPD °I-III):
Working men/women, preferentially taxi drivers or bus drivers or comparable occupational burden, age 35 to 65 yr, current smokers or ex-smokers, with symptoms of COPD, and abnormal lung function at rest at the time of study entry, no signs of significant other diseases, in particular no signs of cardiovascular disease (n=35).
Group 4 (Welder; COPD °0):
Working men/women, active welders or comparable occupational burden, age 35 to 65 yr, current smoker or ex-smoker, with symptoms suggestive of COPD, yet regular lung function test at rest, no signs of significant other diseases, in particular no signs of cardiovascular disease (n=35).
Group 5 (Welder; COPD °I-III):
Working men/women, active welders or comparable occupational burden, age 35 to 65 yr, current smoker or ex-smoker, with symptoms of COPD and abnormal lung function at rest at the time of study entry, no signs of significant other diseases, in particular no signs of cardiovascular disease (n=35).
Exclusion criteria:
* COPD °IV
* Bronchial asthma
* Major cardiovascular diseases, in particular stroke and myocardial infarction with reduced cardiac function
* Age \> 65 years
* Acute or chronic bronchial infections, in particular bronchiectasis
* Cancer
Study investigations
Visit 1 Visit 2 Visit 3 Clinical investigation x x x Blood drawing for laboratory testing x x x Spirometry x x x Body plethysmography x x x Spiro-Ergometry x x x CT Thorax x x x Bronchoscopy with transbronchial biopsy x x x Gene profiling x x x
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Workers of the greater Vienna Area
* Current smokers or ex-smokers
Exclusion Criteria
* Bronchial asthma
* Major cardiovascular diseases, in particular stroke and myocardial infarction with reduced cardiac function
* Age \> 65 years
* Acute or chronic bronchial infection, in particular bronchiectasis
* Cancer
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rolf Ziesche
Associated Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lutz H Block, MD
Role: PRINCIPAL_INVESTIGATOR
Medical University of Vienna
Rolf Ziesche, MD
Role: STUDY_DIRECTOR
Medical University of Vienna
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Pulmonary Medicine, Medical University of Vienna
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Samaha E, Vierlinger K, Weinhappel W, Godnic-Cvar J, Nohammer C, Koczan D, Thiesen HJ, Yanai H, Fraifeld VE, Ziesche R. Expression Profiling Suggests Loss of Surface Integrity and Failure of Regenerative Repair as Major Driving Forces for Chronic Obstructive Pulmonary Disease Progression. Am J Respir Cell Mol Biol. 2021 Apr;64(4):441-452. doi: 10.1165/rcmb.2020-0270OC.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COPD-AUVA
Identifier Type: -
Identifier Source: org_study_id